AMAZE 7NCT07668414
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Study sites: 43 to 45
- Eligibility criteria expanded, about 5 words
- Minor Trial sites reduced: 46 → 43 locationsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Participants will receive Zenagamtide and placebo matched to semaglutide subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Participants will receive semaglutide dose 1 and placebo matched to zenagamtide subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Participants will receive semaglutide dose 2 and placebo matched to zenagamtide subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drugs: Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide)
Sites
45 sites in 1 country